Estrogen and thrombosis: Controversies and common sense

Reviews in Endocrine and Metabolic Disorders

Volumn 12, Issue 2, 2011, Pages 77-84

  Deloughery, Thomas G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Estrogen; Myocardial infraction; Stroke; Thrombophilia; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; PROTEIN C; PROTHROMBIN; SEX HORMONE BINDING GLOBULIN; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; AGING; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMBINED HORMONAL CONTRACEPTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; FIBRINOLYSIS; GENE MUTATION; HEART INFARCTION; HEMOSTASIS; HIRSUTISM; HORMONAL CONTRACEPTION; HYPERTENSION; INCIDENCE; INTRAUTERINE CONTRACEPTIVE DEVICE; OBESITY; ORAL CONTRACEPTION; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCREENING; SMOKING; STROKE; THROMBOGENICITY; THROMBOPHILIA; TRANSDERMAL PATCH; VAGINA RING; VEIN THROMBOSIS; VON WILLEBRAND DISEASE;

ADULT; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; HEMOSTATIC DISORDERS; HUMANS; RISK FACTORS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 79958149914     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9178-0     Document Type: Article

References (64)

1. FR Rosendaal A Van Hylckama Vlieg BC Tanis FM Helmerhorst 2003 Estrogens, progestogens and thrombosis J Thromb Haemost 1 7 1371 80 12871270 10.1046/j.1538-7836.2003.00264.x 1:CAS:528:DC%2BD2cXktFOjs7Y%3D
2. CL Shufelt CN Bairey Merz 2009 Contraceptive hormone use and cardiovascular disease J Am Coll Cardiol 53 3 221 31 19147038 10.1016/j.jacc.2008.09.042 1:CAS:528:DC%2BD1MXntFejsA%3D%3D
3. BC Tanis MA van den Bosch JM Kemmeren, et al. 2001 Oral contraceptives and the risk of myocardial infarction N Engl J Med 345 25 1787 93 11752354 10.1056/NEJMoa003216 1:CAS:528:DC%2BD38Xltl2jtA%3D%3D
4. Hormones and cardiovascular health in women (2006) Hum Reprod Update 12(5): 483-497
5. BC Tanis 2003 Oral contraceptives and the risk of myocardial infarction Eur Heart J 24 5 377 80 12633537 10.1016/S0195-668X(02)00752-2 1:CAS:528:DC%2BD3sXhvFGqt7o%3D (Pubitemid 36286178)
6. C Seibert E Barbouche J Fagan E Myint T Wetterneck M Wittemyer 2003 Prescribing oral contraceptives for women older than 35 years of age Ann Intern Med 138 1 54 64 12513046 (Pubitemid 36232094)
7. JM Kemmeren BC Tanis MA van den Bosch, et al. 2002 Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke Stroke 33 5 1202 8 11988591 10.1161/01.STR.0000015345.61324.3F (Pubitemid 34517036)
8. SA Pitts SJ Emans 2008 Controversies in contraception Curr Opin Pediatr 20 4 383 9 18622191 10.1097/MOP.0b013e328305e13f
9. MA van den Bosch JM Kemmeren BC Tanis, et al. 2003 The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women J Thromb Haemost 1 3 439 44 10.1046/j.1538-7836.2003.00079.x
10. O Lidegaard E Lokkegaard AL Svendsen C Agger 2009 Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 b2890 19679613 10.1136/bmj.b2890
11. LA Heinemann JC Dinger 2007 Range of published estimates of venous thromboembolism incidence in young women Contraception 75 5 328 36 17434013 10.1016/j.contraception.2006.12.018 (Pubitemid 46551070)
12. T Battaglioli I Martinelli 2007 Hormone therapy and thromboembolic disease Curr Opin Hematol 14 5 488 93 17934355 1:CAS:528:DC%2BD2sXhtVenurbN (Pubitemid 47457638)
13. VA van Hylckama FM Helmerhorst JP Vandenbroucke CJ Doggen FR Rosendaal 2009 The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study BMJ 339 b2921 10.1136/bmj.b2921
14. Sitruk-Ware R, Nath A (2011) Metabolic effects of contraceptive steroids. Reviews in endocrine and metabolic disorders In Press
15. JD Curb RL Prentice PF Bray, et al. 2006 Venous thrombosis and conjugated equine estrogen in women without a uterus Arch Intern Med 166 7 772 80 16606815 10.1001/archinte.166.7.772 1:CAS:528:DC%2BD28Xktlymu7c%3D
16. JT Jensen 2010 Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest Expert Opin Pharmacother 11 7 1147 57 20367275 10.1517/14656561003724713 1:CAS:528:DC%2BC3cXntVyqt7s%3D
17. JD Seeger J Loughlin PM Eng CR Clifford J Cutone AM Walker 2007 Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives Obstet Gynecol 110 3 587 93 17766604 10.1097/01.AOG.0000279448. 62221.a8 1:CAS:528:DC%2BD2sXhtVOku7vI (Pubitemid 47359582)
18. JM Kemmeren A Algra DE Grobbee 2001 Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ 323 7305 131 4 11463678 10.1136/bmj.323.7305.131 1:STN:280:DC%2BD3MvhsVSmsw%3D%3D (Pubitemid 32678382)
19. RD Farmer RA Lawrenson JC Todd, et al. 2000 A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives Br J Clin Pharmacol 49 6 580 90 10848722 10.1046/j.1365-2125. 2000.00198.x 1:STN:280:DC%2BD3czgslejtw%3D%3D (Pubitemid 30326558)
20. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World health organization collaborative study of cardiovascular disease and steroid hormone contraception (1995) Lancet 346(8990): 1582-1588
21. RDT Farmer RA Lawrenson CR Thompson JG Kennedy IR Hambleton 1997 Population-based study of risk of venous thromboembolism associated with various oral contraceptives Lancet 349 83 8 8996419 10.1016/S0140-6736(96)07496-X 1:STN:280:DyaK2s7kvFKisw%3D%3D (Pubitemid 27023424)
22. S Jick JA Kaye L Li H Jick 2007 Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol Contraception 76 1 4 7 17586129 10.1016/j.contraception.2007.03.003 1:CAS:528:DC%2BD2sXmvVOht78%3D (Pubitemid 46935110)
23. N Weiss 1995 Third-generation oral contraceptives: how risky? Lancet 346 8990 1570 7500743 10.1016/S0140-6736(95)91921-X 1:STN:280:DyaK287gs1ahsg%3D%3D (Pubitemid 26001833)
24. PC Hannaford 2011 Epidemiology of the contraceptive pill and venous thromboembolism Thromb Res 127S3 S30 4 10.1016/S0049-3848(11)70009-3
25. R Sitruk-Ware A Nath 2010 The use of newer progestins for contraception Contraception 82 5 410 7 20933114 10.1016/j.contraception.2010.04.004 1:CAS:528:DC%2BC3cXht1Kqs7bI
26. N Sehovic KP Smith 2010 Risk of venous thromboembolism with drospirenone in combined oral contraceptive products Ann Pharmacother 44 5 898 903 20371756 10.1345/aph.1M649 1:CAS:528:DC%2BC3cXmtlWnurw%3D
27. HM Pearce D Layton LV Wilton SA Shakir 2005 Deep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin Br J Clin Pharmacol 60 1 98 102 15963100 10.1111/j.1365-2125.2005.02373.x (Pubitemid 40942787)
28. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151
29. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139
30. JC Dinger LA Heinemann D Kuhl-Habich 2007 The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation Contraception 75 5 344 54 17434015 10.1016/j.contraception.2006.12. 019 1:CAS:528:DC%2BD2sXkt1eju7Y%3D (Pubitemid 46551071)
31. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ. 2011;342:d2519
32. VA van Hylckama FM Helmerhorst FR Rosendaal 2010 The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device Arterioscler Thromb Vasc Biol 30 11 2297 300 10.1161/ATVBAHA.110.211482
33. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World health organization collaborative study of cardiovascular disease and steroid hormone contraception (1995) Lancet 346(8990): 1575-1582.
34. SS Jick KW Hagberg JA Kaye 2010 ORTHO EVRA and venous thromboembolism: an update Contraception 81 5 452 3 20399954 10.1016/j.contraception.2009.12.016
35. DD Dore H Norman J Loughlin JD Seeger 2010 Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users Contraception 81 5 408 13 20399947 10.1016/j.contraception.2009.12.009 1:CAS:528:DC%2BC3cXkvFKqs7k%3D
36. K Fleischer HA van Vliet FR Rosendaal J Rosing S Tchaikovski FM Helmerhorst 2009 Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study Thromb Res 123 3 429 35 18829069 10.1016/j.thromres.2008.04.022 1:CAS:528:DC%2BD1cXhsFCls7fI
37. MW van den Heuvel AJ van Bragt AK Alnabawy MC Kaptein 2005 Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 72 3 168 74 16102549 10.1016/j.contraception.2005.03.005 (Pubitemid 41133355)
38. JP Vandenbroucke J Rosing KW Bloemenkamp, et al. 2001 Oral contraceptives and the risk of venous thrombosis N Engl J Med 344 20 1527 35 11357157 10.1056/NEJM200105173442007 1:CAS:528:DC%2BD3MXktF2gsbc%3D (Pubitemid 32429213)
39. AN de Groot PW van Dongen TB Vree TK Eskes 1995 Oral administration of methylergometrine shows a late and unpredictable effect on the non-pregnant human menstruating uterus Eur J Obstet Gynecol Reprod Biol 60 2 101 7 7641959 10.1016/0028-2243(95)02100-7
40. MT DeSancho T Dorff JH Rand 2010 Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy Blood Coagul Fibrinolysis 21 6 534 8 20581664 10.1097/MBC. 0b013e32833b2b84 1:CAS:528:DC%2BC3cXpvFKmtLw%3D
41. D Blickstein I Blickstein 2007 Oral contraception and thrombophilia Curr Opin Obstet Gynecol 19 4 370 6 17625421 10.1097/GCO.0b013e32821642e6 (Pubitemid 47067102)
42. JP Vandenbroucke FJM Van der Meer FM Helmerhorst FR Rosendaal 1996 Factor V Leiden: should we screen oral contraceptive users and pregnant women? Brit Med J 313 1127 30 8916702 1:STN:280:DyaK2s%2FnsVaktg%3D%3D (Pubitemid 26362955)
43. SN Tchaikovski J Rosing 2010 Mechanisms of estrogen-induced venous thromboembolism Thromb Res 126 1 5 11 20163835 10.1016/j.thromres.2010.01.045 1:CAS:528:DC%2BC3cXnsVaktbo%3D
44. AH James 2009 Venous thromboembolism in pregnancy Arterioscler Thromb Vasc Biol 29 3 326 31 19228606 10.1161/ATVBAHA.109.184127 1:CAS:528: DC%2BD1MXhs1CgtLg%3D
45. U Goebelsmann CA Mashchak DR Mishell Jr 1985 Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol Am J Obstet Gynecol 151 7 868 77 3920910 1:CAS:528:DyaL2MXhvFyhs7o%3D (Pubitemid 15237723)
46. V Olie M Canonico PY Scarabin 2011 Postmenopausal hormone therapy and venous thromboembolism Thromb Res 127 Suppl 3 S26 9 21262434 10.1016/S0049-3848(11)70008-1 1:CAS:528:DC%2BC3MXivVWgsb4%3D
47. JT Jensen AE Burke KT Barnhart C Tillotson M Messerle-Forbes D Peters 2008 Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis Contraception 78 6 451 8 19014790 10.1016/j. contraception.2008.07.004 1:CAS:528:DC%2BD1cXhtlyitLvK
48. JM Kemmeren A Algra JC Meijers, et al. 2004 Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial Blood 103 3 927 33 14551147 10.1182/blood-2003-04-1285 1:CAS:528:DC%2BD2cXhtValu7Y%3D (Pubitemid 38129552)
49. DA Grimes KF Schulz EG Raymond 2010 Surrogate end points in women's health research: science, protoscience, and pseudoscience Fertil Steril 93 6 1731 4 20153470 10.1016/j.fertnstert.2009.12.054
50. M Martineau C Nelson-Piercy 2009 Venous thromboembolic disease and pregnancy Postgrad Med J 85 1007 489 94 19734517 10.1136/pgmj.2009.079822 1:STN:280:DC%2BD1MngvVSqtQ%3D%3D
51. IA Greer 1999 Thrombosis in pregnancy: maternal and fetal issues Lancet 353 9160 1258 65 10217099 10.1016/S0140-6736(98)10265-9 1:STN:280: DyaK1M3jtFCmsw%3D%3D (Pubitemid 29168473)
52. Royal College of Obstetricains and Gynaecologists (2010) Venous thromboembolism and hormonal contraception, Green-top Guideline No. 40., pp. 1-13
53. PC Hannaford L Iversen TV Macfarlane AM Elliott V Angus AJ Lee 2010 Mortality among contraceptive pill users: cohort evidence from royal college of general practitioners' oral contraception study Brit Med J 340 c927 20223876 10.1136/bmj.c927
54. S Hicks T DeLoughery A Edelman 2008 Menstrual regulation in women with von Willebrand's disease Int J Gynaecol Obstet 102 1 80 1 18313057 10.1016/j.ijgo.2008.01.020
55. IS Fraser RJ Porte PA Kouides AS Lukes 2008 A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding Drug Saf 31 4 275 82 18366238 10.2165/00002018-200831040-00001 1:CAS:528:DC%2BD1cXmtlOltbg%3D (Pubitemid 351441576)
56. AM Kaunitz F Bissonnette I Monteiro E Lukkari-Lax C Muysers JT Jensen 2010 Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial Obstet Gynecol 116 3 625 32 20733445 10.1097/AOG.0b013e3181ec622b 1:CAS:528:DC%2BC3cXhtFyit7bO
57. AS Lukes B Reardon G Arepally 2008 Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders Fertil Steril 90 3 673 7 18001734 10.1016/j.fertnstert.2007.07.1315
58. C Chi FY Huq RA Kadir 2011 Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up Contraception 83 3 242 7 21310286 10.1016/j.contraception.2010.07.010 1:CAS:528:DC%2BC3MXhvVyrtrw%3D
59. SC Christiansen SC Cannegieter T Koster JP Vandenbroucke FR Rosendaal 2005 Thrombophilia, clinical factors, and recurrent venous thrombotic events JAMA 293 19 2352 61 15900005 10.1001/jama.293.19.2352 1:CAS:528: DC%2BD2MXktlalsro%3D (Pubitemid 40676757)
60. WM Lijfering NJ Veeger S Middeldorp, et al. 2009 A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families Blood 114 10 2031 6 19571315 10.1182/blood-2009-04-215418 1:CAS:528:DC%2BD1MXhtFKksL3J
61. PA Kyrle FR Rosendaal S Eichinger 2010 Risk assessment for recurrent venous thrombosis Lancet 376 9757 2032 9 21131039 10.1016/S0140-6736(10)60962-2
62. E Hoibraaten E Qvigstad H Arnesen S Larsen E Wickstrom PM Sandset 2000 Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET) Thromb Haemost 84 6 961 7 11154141 1:CAS:528:DC%2BD3MXlvFaltg%3D%3D (Pubitemid 32014029)
63. MM Zingone AB Guirguis A Airee D Cobb 2009 Probable drug interaction between warfarin and hormonal contraceptives Ann Pharmacother 43 12 2096 102 19934391 10.1345/aph.1M382
64. N Dunn 2009 Oral contraceptives and venous thromboembolism Brit Med J 339 b3164 19679617 10.1136/bmj.b3164